Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

<< Previous

Bullboard Posts

Next >>

Post by NotinKansason Nov 30, 2021 8:28am

428 Views

Post# 34179154

4 or 5 new CRs at 90 days?

I see some here referring to four new CRs and one PR being reported, but if I compare the upper, total results graph in the previous newsletter with the upper, total results table in the current newsletter, it suggests to me that actually all of the five new evaluable patients are CR at 90 days. The Q2 graph had 33% of 27 which makes for 9 CRs, and according to the new data we stand at 14, with the number of PRs and NRs stable at respectively 4 and 8. Or am I overlooking something?

<< Previous

Bullboard Posts

Next >>

This AI stock is disrupting the event tickets monopoly